Abstract
In recent years, two different methods have been developed to image cell proliferation with the functional imaging technique, Positron emission Tomography (PET), proliferation rate and proliferative status. Proliferation rate is a measure of the tumor doubling time and uses radiolabeled analogs of the DNA precursor thymidine. This approach measures the activity of the enzyme thymidine kinase 1 (TK1) and provides a pulse label of the S phase fraction of a tumor. Proliferative status provides a measure of the ratio of proliferating (P) and quiescent (Q) cells in a tumor. This imaging approach for measuring proliferative status involves measuring the sigma-2 (σ2) receptor status of a tumor, the only protein which has been validated for making this measurement in vivo with PET. This article provides an overview of the biological information obtained from these different imaging strategies, and the development of radiotracers for imaging proliferation rate and proliferative status.
Keywords: Cell proliferation, DNA synthesis, positron emission tomography, radiotracer, sigma-2 receptors.
Current Topics in Medicinal Chemistry
Title:Development of 18F-Labeled PET Probes for Imaging Cell Proliferation
Volume: 13 Issue: 8
Author(s): Kiran Kumar Solingapuram Sai, Lynne A. Jones and Robert H. Mach
Affiliation:
Keywords: Cell proliferation, DNA synthesis, positron emission tomography, radiotracer, sigma-2 receptors.
Abstract: In recent years, two different methods have been developed to image cell proliferation with the functional imaging technique, Positron emission Tomography (PET), proliferation rate and proliferative status. Proliferation rate is a measure of the tumor doubling time and uses radiolabeled analogs of the DNA precursor thymidine. This approach measures the activity of the enzyme thymidine kinase 1 (TK1) and provides a pulse label of the S phase fraction of a tumor. Proliferative status provides a measure of the ratio of proliferating (P) and quiescent (Q) cells in a tumor. This imaging approach for measuring proliferative status involves measuring the sigma-2 (σ2) receptor status of a tumor, the only protein which has been validated for making this measurement in vivo with PET. This article provides an overview of the biological information obtained from these different imaging strategies, and the development of radiotracers for imaging proliferation rate and proliferative status.
Export Options
About this article
Cite this article as:
Sai Kiran Kumar Solingapuram, Jones Lynne A. and Mach Robert H., Development of 18F-Labeled PET Probes for Imaging Cell Proliferation, Current Topics in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/1568026611313080003
DOI https://dx.doi.org/10.2174/1568026611313080003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy
Current Medicinal Chemistry MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews SALL4: Engine of Cell Stemness
Current Gene Therapy Epidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Current Drug Targets Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Bisphosphonate Anticancer Activity in Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Auraptene: A Natural Biologically Active Compound with Multiple Targets
Current Drug Targets Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry In vivo Real-Time Near-Infrared Fluorescent Mapping of Sentinel Lymph Nodes Using Methylene Blue Encapsulated in a Microemulsion Nanosystem
Current Nanoscience Alternative Splicing Regulates Pluripotent State in Pluripotent Stem Cells
Current Stem Cell Research & Therapy Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Aging and DNA Methylation
Current Chemical Biology ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Anti-cancer Effects of a Neutral Triterpene Fraction from Ganoderma lucidum and its Active Constituents on SW620 Human Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry